2023年7月13日

谷别墅、纽约、美国纽瓦克德尔,2023年7月13日(全球通讯社)——全球免疫组织化学(包含IHC)市场规模预计将达到2023年近21亿美元的价值由于其快速扩张。免疫组织化学的需求预计将在未来几年显著增加的复合年增长率预计从2023年到2033年的8.8%。这个市场,到2033年,全球预计将进一步增长,达到49亿美元的价值。病理学和分子生物学两个广泛使用免疫组织化学的方法来揭示重要细节细胞组成,操作,和病理状态。免疫组织化学是广泛应用于生物医学研究在几个领域,包括癌症研究、药物开发和诊断病理学。免疫组织化学的有效性和精度通过技术和自动化的改进使它增加了负担得起的和实际的临床应用范围。此外,过程已经简化,减少周转时间,与自动化平台,多路染色方法和数字成像系统。深潜水:访问样本报告了解航运业和绿色氢措施推动免疫组织化学市场:https://www.futuremarketinsights.com/reports/sample/rep - gb - 14808生物标志物评估需求扩大与增加的重点有针对性的药物,病人要求准确分类基于分子分析。因此,预计需要免疫组织化学的诊断可能是由日益增长的老年人口容易慢性疾病。最重要的是,市场扩大的意识上升早期疾病检测和正确的诊断的价值。 Key Takeaways from this Market Study: Geographically, the United States controlled 38.8% of the global market in 2022 because of the region's developed healthcare infrastructure, and high healthcare spending. The demand for immunohistochemistry-based diagnostics in the United Kingdom is being fueled by the rising prevalence of chronic illnesses and the growing elderly population. However, over the next ten years, this regional market is anticipated to witness an annual average growth rate of only 3.9%. FMI projects that the Asia Pacific region could see substantial development in the adoption of immunohistochemistry, mostly because of the region's expanding healthcare infrastructure. Particularly, China and India have increased investments in the biotechnology and pharmaceutical industries, and are expected to witness 9.3% and 8.7% CAGRs through 2033 respectively. Elevate Your Experience with Personalized Excellence: Customize Perfection at a Discounted Price: https://www.futuremarketinsights.com/customization-available/rep-gb-14808 Recent Developments by the Immunohistochemistry Market Players: The debut of Abcam, PLC's new line of immunohistochemistry primary antibodies was announced in June 2023. The company claims the purpose of these antibodies is to enhance the identification of particular proteins in tissue samples. A new series of automated immunohistochemistry kits from DakoEnVision Company was introduced by Merck KGaA in May 2023. These improved kits are designed and intended to increase the IHC testing's sensitivity and specificity. Agilent Technologies Incorporation, a manufacturer of automated immunohistochemistry systems, announced in March 2023 that it had acquired Amnis Corporation. Agilent now can access new customers and diversify its IHC product line after this purchase. Thermo Fisher Scientific Incorporation declared the release of their new PathXL immunohistochemistry software in April 2023. This new program is intended to make it easy for pathologists to correctly interpret immunohistochemistry data. F. Hoffmann-La Roche AG declared the release of its brand-new Ventana Benchmark XT automated IHC system in February 2023. The system's prominent role is to increase the precision and effectiveness of immunohistochemistry diagnostics or testing. The top 9 Key Players Involved are: Thermo Fisher